(DFTX) Definium Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.143m USD | Total Return: 218.3% in 12m
Avg Turnover: 31.4M
Warnings
Share dilution 24.9% YoY
Interest Coverage Ratio -13.3 is critical
Altman Z'' -9.96 < 1.0 - financial distress zone
Tailwinds
Leader, Tailwind, Pullback 52w
Definium Therapeutics, Inc. (DFTX), formerly known as Mind Medicine (MindMed) Inc., is a clinical-stage biopharmaceutical company headquartered in New York. The firm focuses on developing therapies for brain health disorders, currently advancing two primary clinical programs. Their lead candidate, DT120, is in Phase 3 trials for generalized anxiety and major depressive disorders, while DT402 is undergoing Phase 2a trials for autism spectrum disorder.
Operating within the pharmaceutical sector, Definium utilizes a research-intensive business model characterized by high capital expenditures and long developmental timelines common to neuro-psychiatric drug discovery. The company’s focus on R-enantiomers and novel compounds reflects a broader industry trend toward precision medicine in mental health, where regulatory approval hinges on demonstrating both superior safety profiles and clinical efficacy over existing generic treatments.
Investors can evaluate these clinical milestones and market positioning further by reviewing the detailed metrics available on ValueRay.
- Phase 3 clinical trial results for DT120 determine near-term commercial viability
- FDA approval timeline for lead candidates dictates long-term revenue potential
- Research and development expenditures influence cash runway and future equity dilution
- Phase 2a data for DT402 impacts market valuation of autism spectrum pipeline
- Regulatory shifts in psychedelic-derived medicinal classification affect institutional investor sentiment
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA -2.41 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.36 > 3% & CFO -143.7m > Net Income -237.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (108.8m) vs 12m ago 24.92% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -13.29 > 6 (EBITDA TTM -192.7m / Interest Expense TTM 14.6m) |
| A: 0.75 (Total Current Assets 380.6m - Total Current Liabilities 81.1m) / Total Assets 401.3m |
| B: -1.64 (Retained Earnings -659.8m / Total Assets 401.3m) |
| C: -0.57 (EBIT TTM -193.4m / Avg Total Assets 338.3m) |
| D: -5.38 (Book Value of Equity -658.9m / Total Liabilities 122.4m) |
| Altman-Z'' = -9.96 = D |
As of May 24, 2026, the stock is trading at USD 22.65 with a total of 2,113,516 shares traded.
Over the past week, the price has changed by +7.19%,
over one month by -2.51%,
over three months by +32.74% and
over the past year by +218.25%.
Definium Therapeutics has no consensus analysts rating.
Revenue TTM = 0.0 USD
EBIT TTM = -193.4m USD
EBITDA TTM = -192.7m USD
Long Term Debt = 40.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = unknown (none)
Debt = 72.0k USD (Leases only: 72.0k)
Net Debt = -373.4m USD (calculated: Debt 72.0k - CCE 373.4m)
Enterprise Value = 1.77b USD (2.14b + Debt 72.0k - CCE 373.4m)
Interest Coverage Ratio = -13.29 (Ebit TTM -193.4m / Interest Expense TTM 14.6m)
EV/FCF = -12.32x (Enterprise Value 1.77b / FCF TTM -143.7m)
FCF Yield = -8.12% (FCF TTM -143.7m / Enterprise Value 1.77b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 4.41 (Enterprise Value 1.77b / Total Assets 401.3m)
Interest Expense / Debt = 20.2k% (Interest Expense 14.6m / Debt 72.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -152.8m (EBIT -193.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.69 (Total Current Assets 380.6m / Total Current Liabilities 81.1m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 278.8m)
Debt / EBITDA = 1.94 (negative EBITDA) (Net Debt -373.4m / EBITDA -192.7m)
Debt / FCF = 2.60 (negative FCF - burning cash) (Net Debt -373.4m / FCF TTM -143.7m)
Total Stockholder Equity = 231.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -70.22% (Net Income -237.5m / Total Assets 401.3m)
RoE = -26.64% (Net Income TTM -237.5m / Total Stockholder Equity 891.6m)
RoCE = -20.74% (EBIT -193.4m / Capital Employed (Equity 891.6m + L.T.Debt 40.6m))
RoIC = -47.71% (negative operating profit) (NOPAT -152.8m / Invested Capital 320.2m)
WACC = 10.86% (E(2.14b)/V(2.14b) * Re(10.86%) + (debt cost/tax rate unavailable))
Discount Rate = 10.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 55.52%
[DCF] Fair Price = unknown (Cash Flow -143.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.88 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.57 | Chg30d=-15.41% | Revisions=-20% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.56 | Chg30d=-12.93% | Revisions=-20% | Analysts=11
EPS current Year (2026-12-31): EPS=-2.27 | Chg30d=-17.50% | Revisions=-60% | GrowthEPS=-10.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.58 | Chg30d=+7.50% | Revisions=+0% | GrowthEPS=+30.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -60%